Plasma levels of amyloid β 40 and 42 are independent from ApoE genotype and mental retardation in down syndrome

American Journal of Medical Genetics

Volumn 95, Issue 3, 2000, Pages 224-228

  Cavani, Simona ^a   Tamaoka, Akira ^b   Moretti, Aldo ^c   Marinelli, Lucio ^d   Angelini, Giovanna ^e   Stefano, Sara Di ^c   Piombo, Giuseppe ^a   Cazzulo, Virginia ^c   Matsuno, Sayoko ^b   Shoji, Shin'ichi ^b   Furiya, Yoshiko ^f   Zaccheo, Damiano ^d   Dagna Bricarelli, Francesca ^a   Tabaton, Massimo ^d   Mori, Hiroshi ^f  

^a GALLIERA HOSPITAL   (Italy)

^b UNIVERSITY OF TSUKUBA   (Japan)

^c CEPIM   (Italy)

^d UNIVERSITY OF GENOA   (Italy)

^e UNIVERSITY OF GENOA   (Italy)

^f OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Amyloid protein; Apolipoprotein E; Biological fluids; Down syndrome; Plasma

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; BIOACCUMULATION; BRAIN LEVEL; CONTROLLED STUDY; DOWN SYNDROME; GENE EXPRESSION; GENOTYPE; HUMAN; INTELLIGENCE QUOTIENT; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MENTAL DEFICIENCY; PLASMA CLEARANCE; PRIORITY JOURNAL; RATING SCALE;

ADOLESCENT; ADULT; AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; APOLIPOPROTEINS E; CASE-CONTROL STUDIES; CHILD; COHORT STUDIES; DOWN SYNDROME; GENOTYPE; HUMANS; MENTAL RETARDATION; MIDDLE AGED; PEPTIDE FRAGMENTS; STATISTICS, NONPARAMETRIC;

EID: 0034722843     PISSN: 01487299     EISSN: None     Source Type: Journal    
DOI: 10.1002/1096-8628(20001127)95:3<224::AID-AJMG7>3.0.CO;2-B     Document Type: Article

References (25)

1. Long amyloid beta-protein secreted from wild-type human neuroblastoma IMR-32 cells
2. Generation and regulation of beta-amyloid peptide variants by neurons
3. Endoplasmic reticulum and trans-Golgi network generate distinct populations of Alzheimer beta-amyloid peptides
4. Amyloid beta-peptide is produced by cultured cells during normal metabolism
5. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI
6. Expression of human apolipoprotein E reduces amyloid-beta deposition in a mouse model of Alzheimer disease
7. Analysis of heterogeneous A4 peptides in human cerebrospinal fluid and blood by a newly developed sensitive Western blot assay
8. Visualization of Aβ 42(43) and Aβ 40 in senile plaques with end-specific Aβ monoclonals: Evidence that an initially deposited species is Aβ 42(43)
9. The beta APP717 Alzheimer mutation increases the percentage of plasma amyloid-beta protein ending at Aβ42(43)
10. The soluble form of Alzheimer amyloid beta protein is complexed to high density lipoprotein 3 and very high density lipoprotein in normal human plasma
11. Sequence of deposition of heterogeneous amyloid beta-peptides and APO E in Down syndrome: Implications for initial events in amyloid plaque formation
12. Lipoprotein-free amyloidogenic peptides in plasma are elevated in patients with sporadic Alzheimer disease and Down syndrome
13. Increased plasma amyloid beta protein 1-42 levels in Down syndrome
14. Early glycoxidation damage in brains from Down syndrome
15. Amyloid A4 protein and its precursor in Down syndrome and Alzheimer disease
16. Opposite roles of apolipoprotein E in normal brains and in Alzheimer disease
17. Heterogeneity of water-soluble amyloid beta-peptide in Alzheimer disease and Down syndrome brains
18. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer disease
19. Onset of dementia is associated with apolipoprotein E ε4 in Down syndrome
20. Normal and abnormal biology of the beta-amyloid precursor protein
21. Isolation and quantification of soluble Alzheimer beta-peptide from biological fluids
22. Production of the Alzheimer amyloid beta protein by normal proteolytic processing
23. Presence of soluble amyloid beta-peptide precedes amyloid plaque formation in Down syndrome
24. Plasma levels of amyloid beta proteins Aβ1-40 and Aβ1-42(43) are elevated in Down syndrome
25. Characterization of β-amyloid peptide from human cerebrospinal fluid